With the development of PSMA-617 showing an improved and fast kidney excretion, a highly promising compound is already being clinically investigated for endoradiotherapy of prostate cancer with 177Lu or 225Ac [15,16,17]. This evidence concerns the gene FOLH1 and prostate cancer.